Therapeutic Goods (Manufacturing Principles) Determination 2020

The Determination rests on a small set of repeated structural concepts: incorporation by reference, category-based application, the elevated status of “should” obligations, regulator satisfaction as the gate for permitted departures, and technical master file/plasma master file requirements.

Incorporation by reference: The instrument does not itself set procedural detail for manufacturing. Instead it incorporates the PIC/S Guide to GMP for a broad class of therapeutic goods (Schedule 1, Part 1(1)) and the Australian Code of Good Manufacturing Practice for another class (Schedule 1, Part 2(1)). The definitions section specifies the exact versions and cut‑off dates for those external documents (s 4). For the PIC/S Guide the Determination also expressly excludes certain Annexes (s 4 definition of PIC/S Guide to GMP). This makes the foreign and domestic technical documents part of the legal manufacturing principles that manufacturers must observe.

Category-based application: The Determination divides therapeutic goods into distinct regulatory categories and applies different manufacturing frameworks accordingly. Section 6 directs PIC/S-based principles to all therapeutic goods for human use except those listed in s 7(a)-(d). Section 7 directs the Australian Code to the manufacture of biologicals that do not involve live animal cells/tissues/organs, blood, blood components and haematopoietic progenitor cells (s 7 and Schedule 1, Part 2). Note the instrument clarifies that biologicals that do involve live animal cells, tissues or organs fall under Part 1 and therefore the PIC/S Guide (s 7 Note 1).

Treatment of normative language: The instrument expressly addresses the normative weight of words used in the imported guides. Where a procedure or requirement in the PIC/S Guide or the Australian Code is expressed using the word “should”, the manufacturer must follow it in order to comply with the incorporated document unless one of two limited exceptions is satisfied: either the manufacturer demonstrates to the satisfaction of a relevant officer that the failure to adopt the procedure will not increase risks or depart from record-keeping requirements, or the manufacturer demonstrates that an adopted alternative will not increase risks or depart from record-keeping requirements (Schedule 1, Part 1(2)(a)-(b); Part 2(6)(a)-(b)). Thus, the Determination converts a large body of guidance-style language into an enforceable compliance standard subject to administrative discretion.

Regulator-focused assessment: The recurring assessment point is “to the satisfaction of a relevant officer” (Schedule 1, Part 1(2); Part 2(6)). The relevant officer is defined as an officer of the Therapeutic Goods Administration (s 4). The Determination therefore vests the TGA (through its officers) with judgement on whether a departure or an alternative meets the statutory tests. The demonstrations required are specified substantively in three limbs: no increased risk of harm or injury, no increased risk of failing to comply with applicable standards or conditions, and no departure from applicable record-keeping requirements (Schedule 1, Part 1(2)(a)(i)-(iii); Part 1(2)(b)(i)-(iii); Part 2(6)(a)(i)-(iii); Part 2(6)(b)(i)-(iii)).

Documentation and master files: For blood-related manufacturing, the instrument imposes documentation requirements: licence applications for carrying out manufacturing steps of blood, blood components or haematopoietic progenitor cells must include a technical master file consistent with the TMF Guideline (Schedule 1, Part 2(3) and s 4 definition of technical master file). Manufacturing must then be consistent with that TMF (Part 2(4)). For plasma sourced from outside Australia that is to be processed in a blood processing plant that processes Australian plasma, the instrument requires submission of a plasma master file prepared per the PMF Guideline and affirmative advice from a relevant officer that the foreign source will not contaminate the Australian product with blood borne pathogens before processing may occur (Part 2(5)).

Temporal and versioning concepts: The Determination fixes the external references to particular versions or to the versions in force at commencement. The PIC/S Guide is the document as in force at 1 September 2025 (s 4); the Australian Code is Version 1.0 April 2013 (s 4). The instrument also contains an application clause addressing an amending determination in 2025, and dates on which that amendment applies to manufacturing (s 8(2)-(3)). These timing provisions alter the legal rules by date of manufacture and by product type (sterile therapeutic goods have a separate earlier date for certain PIC/S clauses, s 8(3)).

Exclusions and limits: The Determination limits what is imported from the external documents. It excludes procedures identified as voluntary in an Annex to the PIC/S Guide from the reference to “applicable procedures and requirements” (Schedule 1, Part 1(3)). It also excludes three PIC/S Annexes substantively in the definition (Annexes 4, 5 and 14) (s 4).

Taken together, these concepts make the Determination a regulatory instrument that turns technical GMP guidance into binding regulatory obligations for manufacturers, imposes documentary prerequisites for licences and cross-border plasma processing, and centralises assessment of deviations with TGA officers using three specified risk and record-keeping criteria.

The Determination affects four classes of actors directly and a number of actors indirectly through those classes.

1. Manufacturers of therapeutic goods for human use (broad class). The instrument applies to the manufacture of therapeutic goods for human use generally and explicitly names active pharmaceutical ingredients and sunscreens as examples captured by the Part 1 framework (s 6; Schedule 1, Part 1(1)). Where a manufacturer produces therapeutic goods other than those specified in s 7(a)-(d), the manufacturer must comply with the PIC/S Guide (Schedule 1, Part 1(1)). Manufacturers of biologicals that comprise or contain live animal cells, tissues or organs are also drawn into Part 1 and the PIC/S Guide, by Note 1 to s 7.

2. Manufacturers of blood, blood components and haematopoietic progenitor cells, and manufacturers of biologicals that do not contain live animal cells/tissues/organs. These manufacturers must comply with the Australian Code of Good Manufacturing Practice (Schedule 1, Part 2(1); s 7). This captures organisations operating blood establishments, blood processing plants, cord blood banks or other facilities manufacturing haematopoietic progenitor cells where the product falls within the definitions in s 4.

3. Licence applicants and licence holders carrying out steps in manufacture of blood, blood components and haematopoietic progenitor cells. An application for a licence to carry out such steps must include a technical master file in relation to those goods (Schedule 1, Part 2(3)). Licence holders are required to ensure that their blood, blood components and haematopoietic progenitor cells are manufactured in a manner consistent with that technical master file (Part 2(4)). Licence holders operating a blood processing plant that processes Australian-collected plasma for products used in Australia may only process plasma collected from sources outside Australia if they submit a PMF and receive advice from a relevant officer that the foreign source will not contaminate the Australian product with blood borne pathogens (Part 2(5)). Therefore entities holding or seeking licences to carry out blood-related manufacturing activities are directly affected.

4. The Therapeutic Goods Administration and its officers. The instrument repeatedly uses the standard “to the satisfaction of a relevant officer” as the test for permitting departures from specified procedures or adopting alternatives (Schedule 1, Part 1(2) and Part 2(6)). The “relevant officer” is defined as an officer of the Therapeutic Goods Administration (s 4). The TGA therefore becomes the decision-maker or gatekeeper for whether a manufacturer’s demonstration or alternative is acceptable.

Indirectly affected actors include:

• Suppliers and contractors in a manufacturer’s compliance chain. Because the Determination elevates many “should” procedures to mandatory status (subject to the regulatory test), suppliers that provide quality assurance tests, contract manufacturing organisations, contract laboratories, cleaning and validation services, or raw material suppliers will experience downstream demand for compliance evidence and record keeping.

• Parties to commercial contracts with manufacturers and licence holders. Contract terms may need to be revised to reflect TMF and PMF obligations, to allocate the cost and liability of producing master files and demonstrating alternatives, and to pass on TGA-directed changes to processes.

• Providers of technical documentation and consultants who prepare TMFs, PMFs, and evidence to satisfy a relevant officer. The instrument’s TMF and PMF requirements will drive demand for specialised technical documentation services consistent with the TMF Guideline and the PMF Guideline (s 4 definitions and Schedule 1, Part 2(3)-(5)).

Who bears the costs and who decides: Manufacturers and licence applicants bear the compliance costs , preparing and maintaining a TMF, assembling PMFs for foreign plasma sources, following the PIC/S Guide or Australian Code, and preparing demonstrations for any departures. The TGA (through relevant officers) decides whether any departure or alternative is acceptable and whether foreign plasma may be processed in a plant that handles Australian product (Schedule 1, Parts 1-2; s 8 for amending determination timing). The Determination therefore shifts compliance costs to the regulated entities and places discretionary decision-making power with the TGA.

The Determination’s reach is defined by its text and by the external documents it imports. Users must check product categorisation carefully: whether a biological comprises live animal cells, tissues or organs determines which Part applies (s 7 and its Note). The inclusion of active pharmaceutical ingredients and sunscreens within the Part 1 example list indicates the PIC/S Frame will apply across small-molecule and many non-cellular products (s 6). For blood-derived products, the TMF/PMF regime creates bespoke documentary obligations for licence processes and for cross‑border plasma processing (Schedule 1, Part 2).

Key duties imposed by the Determination are procedural and documentary, and they are allocated by product category.

General duties for non-blood products (PIC/S subjects)

• Comply with applicable procedures and requirements in the PIC/S Guide to GMP. The manufacture of therapeutic goods to which Part 1 applies "must comply" with applicable procedures and requirements in the PIC/S Guide to GMP (Schedule 1, Part 1(1)). This is a direct duty to align operations with the incorporated Guide.
• Follow procedures worded as “should” in the PIC/S Guide, unless the manufacturer satisfies the three-part test set out in Schedule 1, Part 1(2). Where the PIC/S Guide uses “should”, that recommendation becomes a required action unless a manufacturer either demonstrates to a relevant officer that failure to adopt it will not increase risk or depart from record keeping, or demonstrates that an alternative is acceptable on the same grounds (Part 1(2)(a)-(b)).
• Exclusions for voluntary annex items. The duty to comply with “applicable procedures and requirements” does not include a procedure or requirement specified in an Annex to the PIC/S Guide that is identified as voluntary (Schedule 1, Part 1(3)). Therefore manufacturers are not bound by voluntary Annex items unless they are otherwise captured.

Duties for blood and related products (Australian Code subjects)

• Comply with applicable procedures and requirements in the Australian Code of Good Manufacturing Practice (Schedule 1, Part 2(1)). The manufacture of goods in this category "must comply" with the Australian Code.
• Follow “should” language in the Australian Code. The Determination removes any ambiguity about recommendations in the Australian Code; where the Australian Code provides a procedure "should" be followed, the manufacturer "must" follow it to comply (Part 2(2)).
• Include a technical master file in licence applications. Licence applications to carry out steps in the manufacture of blood, blood components or haematopoietic progenitor cells must include a technical master file in relation to those goods (Part 2(3)). The relevant technical master file is defined in s 4 to include compilations of scientific and technical data consistent with the TMF Guideline and detailed data to satisfy a relevant officer that the goods conform to TGO 102, TGO 94, and TGO 108 as applicable.
• Manufacture in accordance with the technical master file. Blood, blood components and haematopoietic progenitor cells must be manufactured in a manner consistent with the relevant TMF (Part 2(4)).
• Controls on processing foreign plasma in Australian plants. A blood processing plant that processes plasma collected from donors in Australia for Australian product may only process plasma collected from outside Australia for that Australian product if: (a) a plasma master file prepared in accordance with the PMF Guideline has been submitted by the licence holder for that source; and (b) a relevant officer has advised the licence holder that, based on that PMF and the plant’s processes, the foreign plasma will not contaminate Australian product with blood borne pathogens (Part 2(5)).

Regulator-centric duties/rights

• Burden of proof and satisfaction standard. Multiple provisions impose a burden on the manufacturer to demonstrate, to the satisfaction of a relevant officer, that a departure or alternative will not increase risk or depart from record keeping (Schedule 1, Part 1(2); Part 2(6)). The instrument therefore places the evidential burden on the regulated entity and the evaluative discretion with the TGA officer.
• Relevant officer’s advisory role for foreign plasma. The licence holder may not process foreign-sourced plasma in a plant used for Australian product unless a relevant officer has advised that the foreign source will not contaminate the Australian product (Part 2(5)(b)). That is a decision right reserved to the relevant officer.

Rights or permissions implicit in the Determination

• Ability to propose alternatives. The Determination permits a manufacturer to adopt an alternative to a procedure or requirement in the PIC/S Guide or Australian Code, but only where the manufacturer demonstrates to the satisfaction of a relevant officer that the alternative meets the three-part non-increase-of-risk, compliance, and record-keeping tests (Schedule 1, Part 1(2)(b); Part 2(6)(b)). This is a structured pathway to regulatory flexibility, conditioned on regulator acceptance.
• Conditional permission to process foreign plasma. The Determination provides a pathway for processing non-Australian plasma in an Australian plant provided the PMF is submitted and positive advice is given by a relevant officer (Part 2(5)). That is not an automatic right; it is a conditional permission gate-kept by the TGA.
• Exemption from voluntary Annex items. Since voluntary Annex items in the PIC/S Guide are excluded from the “applicable procedures and requirements” reference, manufacturers have the right not to adopt those voluntary Annex procedures as compliance obligations (Schedule 1, Part 1(3)).

Documentation and standards cross-reference duties

• Conformity to specified TGOs. The technical master file must provide detailed scientific and technical data or information that must satisfy a relevant officer that the therapeutic goods conform to TGO 102 for blood/blood components, to TGO 94 for haematopoietic progenitor cells derived from cord blood, and to TGO 108 for donor screening requirements as applicable (s 4 definition of technical master file).

What the Determination does not do explicitly

• The instrument does not itself specify criminal penalties, civil sanctions, or license revocation provisions. It declares what constitutes compliance with manufacturing principles and sets out documentary and procedural obligations, but it does not, within its text, create penalty provisions or enforcement mechanisms by specifying fines or offences. Enforcement powers and penalties would therefore reside in the Act or in other instruments; the Determination does not name those sanctions (see the instrument’s silence as to penalty clauses).

In combination, the duties allocate compliance costs and documentary obligations to manufacturers and licence applicants, while discretionary assessment power and conditional permissions are allocated to the TGA via relevant officers.

The Determination itself does not enumerate specific statutory penalties, fines, or enforcement procedures. Its text creates mandatory obligations and definitions of non-compliance with manufacturing principles, and it places evaluative responsibility in the hands of a “relevant officer”, but it does not set out express enforcement mechanisms such as criminal offences, administrative fines, licence suspension or revocation in this instrument.

What the Determination does establish that is relevant to enforcement:

• Definition of non-compliance with incorporated codes. For manufacturers subject to Part 1, it is a requirement that the manufacture “must comply” with applicable procedures and requirements in the PIC/S Guide to GMP (Schedule 1, Part 1(1)). For Part 2 manufacturers, it is a requirement they “must comply” with the Australian Code (Schedule 1, Part 2(1)). The document states that failure to follow an applicable procedure or requirement set out in the Australian Code of Good Manufacturing Practice will constitute a failure to comply with that Code unless one of the limited, regulator-approved exceptions applies (Part 2(6)). Similarly, Part 1 sets out that failure to follow a PIC/S “should” procedure will be a failure to comply unless the manufacturer satisfies a relevant officer on the prescribed tests (Part 1(2)). The Determination thus defines what conduct constitutes compliance or failure to comply with the adopted manufacturing principles.

• Centrality of relevant officer decisions. The instrument repeatedly requires that the manufacturer must demonstrate, to the satisfaction of a relevant officer, that a departure or alternative will not increase risks and will not depart from record-keeping requirements (Schedule 1, Part 1(2) and Part 2(6)). The relevant officer also has the explicit role of advising licence holders whether foreign plasma may be processed in an Australian plant without risk of contaminating Australian product with blood borne pathogens (Part 2(5)). Enforceability consequently rests on the TGA’s administrative oversight: the TGA officer’s assessment can determine whether a manufacturer’s actions are compliant.

• Implied enforcement linkage to the Act. The Determination is made under s 36 of the Therapeutic Goods Act 1989 (see s 3). The Act contains broader regulatory machinery, including licensing, registration, inclusion conditions and enforcement powers. Although this Determination does not set out penalties, non-compliance with a manufacturing principle established in this instrument will be relevant to the TGA’s regulatory functions under the Act. The instrument does not itself state those consequences, but the placement of the Determination within the Act’s framework means enforcement action under the Act could follow from findings of non-compliance. The Determination does not specify those Act-based enforcement mechanisms or the processes for administrative review or appeals; such mechanisms would need to be located in the Act or other subordinate instruments.

Practical enforcement and compliance consequence pathway, as implied by the instrument:

• Evidence and inspection. The requirement to follow incorporated Guides and to include TMFs/PMFs in licence applications implies an evidentiary regime: officers will examine documentation and processes to determine compliance or acceptability of alternatives. The instrument makes the TGA officer’s satisfaction the pivotal decision point.
• Regulatory discretion. Because the instrument frames departure and alternative approvals as matters that must satisfy a relevant officer, the TGA has de facto discretionary control over whether a manufacturer’s non-standard practices are acceptable. The instrument itself does not prescribe procedural timeframes, standards of proof beyond the three-part test, or rights of review against a relevant officer’s decision.
• No stand-alone penalties specified. The absence of stated penalties in the Determination means parties must refer to the Act and other regulatory instruments for specific consequences such as licence refusal, suspension, cancellation, injunctions, prosecutions or civil penalties.

For a practitioner advising a client, the operational effect is clear: the Determination establishes transferable evidence-based obligations and places the onus on the regulated entity to obtain and maintain regulator satisfaction. Enforcement will be administered through TGA action and licence controls anchored in the Act; legal consequences for non-compliance will therefore depend on how the TGA exercises its powers under the Act in response to non-compliance findings, although those Act-based powers are not stated in this Determination.

The Determination is made under the authority of s 36 of the Therapeutic Goods Act 1989 (see s 3 of the Determination). Its legal effect must be read alongside the Act because the instrument adopts external technical documents as the manufacturing principles that determine compliance under the Act. The Determination therefore functions as a subordinate instrument that operationalises the Act’s requirement for manufacturing principles by prescribing specific external materials and procedures that become enforceable expectations.

Direct cross-references within the instrument:

• Therapeutic Goods Act 1989. The Determination is expressly made under s 36 of the Act (s 3). Many expressions used in the Determination are defined by subsection 3(1) of the Act; the Determination’s s 4 expressly notes that a number of expressions used are defined in the Act (s 4 opening Note). This means definitions in the Act (for example, licence, manufacture, manufacturing principles, therapeutic goods) are intended to have primacy and feed into the meaning of terms used in the Determination.
• Therapeutic Goods Orders (TGOs). The Determination requires that the TMF must satisfy a relevant officer that goods conform to specified TGOs: TGO 102 for blood and blood components, TGO 94 for haematopoietic progenitor cells derived from cord blood, and TGO 108 in relation to donor screening requirements (s 4 definition of technical master file). The TGOs themselves are separate instruments with their own substantive standards. The Determination therefore ties compliance with the incorporated GMP documents to conformity with those TGOs through the TMF process.
• External technical guidelines. The Determination expressly incorporates multiple external guidelines and sets the versions that apply at commencement: PIC/S Guide to GMP (as in force at 1 September 2025, with specified Annex exclusions), the Australian Code of Good Manufacturing Practice (Version 1.0, April 2013), the PMF Guideline (EMEA/CHMP/BWP/3794/03 Rev. 1, 2006), and the TMF Guideline (Third Edition, 2008). Those documents are not part of the Federal Register of Legislation but are incorporated by reference; their content determines technical obligations under the Determination. Because the Determination fixes the version or the date at which the external document is to be taken “as in force”, the interaction with these external documents is time‑sensitive and version‑specific (s 4, Schedule 1 inclusions).

Scope and exclusions that affect interaction:

• PIC/S Annex exclusions. The Determination omits specific Annexes from the PIC/S Guide incorporation, namely Annex 4, Annex 5 and Annex 14 (s 4 definition of PIC/S Guide to GMP). For blood- and plasma-derived medicinal products, Annex 14 is excluded from the PIC/S Guide reference; instead, the Australian Code and TMF/PMF mechanisms govern those products (see s 7 note and Schedule 1, Part 2). That exclusion establishes an interaction in which Australia chooses one domestic code for blood products and the PIC/S Guide for many other products, with express carving out of certain PIC/S Annex material.
• Voluntary annex items. Schedule 1, Part 1(3) states that the reference to “applicable procedures and requirements” does not include a procedure or requirement specified in a PIC/S Annex that is identified as voluntary. That interacts with the PIC/S Guide’s own classification of Annex items and ensures that voluntary Annex recommendations do not become binding through this Determination.
• Licence and regulatory architecture. The Determination’s requirement that TMFs and PMFs be submitted as part of licence applications or before processing foreign plasma is an input into the licensing regime under the Act (Schedule 1, Part 2(3)-(5)). The Determination therefore interacts operationally with the TGA’s licensing processes and with other statutory standards prescribed by TGOs.

Temporal interaction and amendment:

• Amending Determination 2025. Section 8 introduces an amending determination by name (Therapeutic Goods (Manufacturing Principles) Amendment (PIC/S Guide) Determination 2025) and specifies the dates on which the amendment applies to manufacture: generally 1 September 2025, but with an earlier or separate operative date for certain PIC/S clauses for sterile therapeutic goods (s 8(2)-(3)). This creates a temporal interaction where the version of the PIC/S Guide and particular clauses come into force for specified manufacturing from stated dates, affecting how the current Determination will be read against future practice.

Consequential law interactions that the Determination does not itself specify:

• Enforcement and sanctions. The Determination does not set out penalty provisions. Therefore, enforcement and sanctions for non-compliance must be sought in the Act or in other instruments. The Determination’s function is to define what constitutes compliance with manufacturing principles; the Act will set out the consequences of non-compliance, though the Determination itself does not state those consequences.
• Administrative review and procedural rights. The instrument uses discretionary “satisfaction” standards for TGA officers but does not set out appeal or review processes in this text. Any rights to administrative review or merits review would be governed by the Act and general administrative law, not by this Determination itself. The Determination therefore interacts indirectly with administrative law and rights to review but does not alter those procedural regimes in its wording.

For practitioners, the key interaction points to watch are the TGOs named in the TMF definition, the PIC/S Guide and Australian Code versions identified, the PMF and TMF Guideline content required for licence applications or foreign plasma processing, and the amending determination dates in s 8 that change which PIC/S clauses apply and when.

The text provided includes one explicit amendment instrument referenced by name and sets detailed operative dates for that amendment. The Determination itself sets out its name and authority (s 1 and s 3) and fixes the versions of incorporated documents as in force at certain commencement dates (see s 4). The explicit amending instrument and timing provisions are the only amendment history recorded in the instrument as provided.

Apparent amendment instrument and application dates:

• The instrument refers to the Therapeutic Goods (Manufacturing Principles) Amendment (PIC/S Guide) Determination 2025 by name in s 8(1). That amending determination is the only amending instrument named in the provided text.
• Section 8(2) states that the amendment made by item 1 in Schedule 1 to the amending determination applies to the manufacture of therapeutic goods that occurs on or after 1 September 2025. This sets a clear commencement date for that amending change.
• Section 8(3) creates a carve-out for specific PIC/S clauses and a product type: it provides that, despite subsection (2), the amendment made by item 1 in Schedule 1 to the amending determination, only to the extent that it has the effect of incorporating clauses 2.1, 2.3, 7.14 and 9.31 of Annex 1 to the PIC/S Guide to GMP, applies to the manufacture of sterile therapeutic goods that occurs on or after 1 March 2026. That is, those specific clauses take effect later for sterile therapeutic goods.

Versioning fixes and incorporations at commencement:

• The Determination fixes the version or the dates for incorporation at commencement. The PIC/S Guide to GMP is defined as the document PE 009-17, 25 August 2023, “as in force or existing at 1 September 2025” (s 4). The Australian Code of Good Manufacturing Practice is defined as Version 1.0, April 2013, “as in force or existing at the commencement of this instrument” (s 4). The PMF Guideline (EMEA/CHMP/BWP/3794/03 Rev. 1, 2006) and the TMF Guideline (Third Edition, 2008) are likewise defined as in force at commencement (s 4). Those definitional clauses function as version locks at the instrument’s commencement; they thus record the initial textual content that was incorporated.

Limits and exclusions introduced by the Determination:

• The drafters excluded specific PIC/S Annexes from incorporation (s 4 definition lists Annex 4, Annex 5 and Annex 14 as excluded). That exclusion is a material choice recorded in the instrument’s text and forms part of the instrument’s content at commencement.
• The Schedule contains a rule that a procedure or requirement in a PIC/S Annex identified as voluntary does not form part of the reference to “applicable procedures and requirements” (Schedule 1, Part 1(3)). This is a textual limitation present in the instrument.

No other amendments are recorded in the text supplied. The instrument includes a repeated set of provisions in the supplied text, but those repetitions are verbatim reproductions within the supplied material rather than indications of separate amendments. The only explicit amendment identified is the 2025 amending determination and the two operative dates contained in s 8.

For users tracking legal change, the practical implication is:

• Check the amending determination named in s 8 to understand exactly what item 1 in Schedule 1 to that amending determination changes in this instrument. The provided text refers to an amending instrument by name and sets effective dates; the content of that amending instrument must be consulted to see the substantive changes.
• Verify the versions and the dates specified in s 4 and s 8 when assessing which external guidance applies to a particular manufacturing activity, because the Determination fixes external documents to specific versions or to the versions in force at the stated commencement dates.

The instrument itself contains no further historical entries such as earlier versions, repeal history, or replacement instruments in the supplied text.

The Determination as supplied does not record any litigation history. The instrument contains no references to judicial decisions, litigation outcomes, or administrative appeals that have interpreted or challenged its provisions. The text does not cite any cases or describe any judicial review decisions.

What the absence of litigation history in the instrument implies for practitioners:

• The instrument is a subordinate regulatory determination prescribing manufacturing principles and documenting incorporated technical standards and the TGA’s assessment role. The Determination itself is not a judgment and so would not, as a matter of course, contain litigation history. Any litigation history would need to be sought in court records, administrative law decisions or public registers of judicial review that interpret decisions under the Therapeutic Goods Act. None of that is included in the present text.
• Because the Determination makes the satisfaction of a relevant officer a determinative test for departures and for foreign plasma processing (Schedule 1, Parts 1-2), decisions by relevant officers could be the subject of administrative review or merits review under broader administrative law, and such cases could generate litigation. The instrument, however, does not itself describe administrative review processes or appeals rights; those would fall to other statutes or to judicial review principles. The Determination contains no internal mechanism or cross-reference that records such litigation or review steps.

Practical research pointers (based on the instrument’s structure):

• To find litigation or review decisions that concern the Determination’s operation, search administrative law and tribunals databases for matters involving TGA decisions where the relevant officer’s assessment under the manufacturing principles was challenged. The Determination’s reliance on TGA officers as decision-makers means disputes will arise in the context of licence application refusals, conditional approvals or determinations about compliance that feed into TGA enforcement actions under the Act. Such cases are not referenced in this instrument.
• Also check judicial and tribunal records for matters touching the interpretation of clauses such as the “to the satisfaction of a relevant officer” test, the TMF/PMF acceptance process, or TGA assessments of risk regarding foreign plasma sources. Because the Determination itself does not discuss such matters, any litigation would be external to its text.

In short, the supplied Determination contains no litigation history. The practical possibility of litigation exists because the instrument vests discretion in TGA officers and creates compliance obligations; however, examples of litigated disputes or appellate authority are not provided in the instrument and would need to be located outside this text.

This Determination contains a number of textually explicit traps for the unwary manufacturer, licence applicant, or contract party. The pitfalls arise from how it elevates guidance to mandatory status, locks versions, limits what is and is not incorporated, and leaves critical decisions to the satisfaction of TGA officers.

1. “Should” becomes “must” unless the regulator is satisfied. The PIC/S Guide and the Australian Code both use the word “should” in many places. Under Schedule 1, Part 1(2) and Part 2(6), those “should” statements become obligations that the manufacturer must follow to comply unless a manufacturer demonstrates, to the satisfaction of a relevant officer, that failure to adopt the procedure will not increase risk, will not increase the risk of failing to comply with applicable standards, and will not depart from applicable record-keeping requirements. Practically, this means manufacturers cannot simply treat “should” as optional: to depart or to adopt an alternative, they must prepare evidence and meet the TGA’s evaluative standard. The burden of proof and the “satisfaction” standard sit with the manufacturer.

2. “To the satisfaction of a relevant officer” is a discretionary gate. The instrument repeatedly places judgement in the hands of a TGA officer (Schedule 1, Part 1(2); Part 2(6); Part 2(5)(b)). The phrase “to the satisfaction of” is not defined in the Determination and therefore creates administrative discretion. Parties must be prepared to compile robust data and arguments to convince the officer. The Determination gives no procedural timeline or standard of review for those satisfaction decisions; neither does it specify an evidentiary threshold. That leaves operational uncertainty and potential delays.

3. Version locking and timing are precise and could be overlooked. The PIC/S Guide to GMP is defined as the Guide “as in force or existing at 1 September 2025” and includes Annexes except three specified Annexes (s 4). The Australian Code is fixed to a 2013 version. The TMF and PMF Guideline versions are also fixed. Manufacturers must check which version of the external documents are incorporated and whether the amending determination (s 8) applies. There is an additional layer: the amending determination’s item 1 in Schedule 1 applies from 1 September 2025 but certain PIC/S clauses apply later for sterile therapeutic goods (s 8(3) effective 1 March 2026). Misreading the dates could lead to non-compliance or unnecessary operational changes.

4. Exclusions of Annex 14 and others alter expectations for blood products. The PIC/S incorporation explicitly excludes Annex 14, which deals with medicinal products derived from human blood or plasma (s 4). For blood-derived products the Determination instead requires compliance with the Australian Code and TMF/PMF processes (Schedule 1, Part 2). Operators supplying blood products must therefore rely on the domestic Code and TMF/PMF rules rather than on the PIC/S Annex 14 provisions they might be familiar with from other jurisdictions.

5. TMF and PMF obligations are specific and technical. Licence applications for steps in manufacture of blood, blood components or haematopoietic progenitor cells must include a technical master file consistent with the TMF Guideline (Schedule 1, Part 2(3)). Manufacturing then must be consistent with that TMF (Part 2(4)). For processing foreign plasma in plants that handle Australian-collected plasma, a PMF meeting the PMF Guideline must be submitted and a relevant officer must advise no contamination risk before processing may occur (Part 2(5)). These obligations are technical and likely require specialist preparation. Failure to properly assemble or align a TMF/PMF with the specified guideline versions risks licence refusal or a regulator withholding permission to process foreign-sourced plasma.

6. Narrow path for processing foreign plasma in Australian plants. Part 2(5) contains a stringent test: if a blood processing plant processes Australian-collected plasma for products used in Australia, that plant may only process foreign-sourced plasma for the Australian product if a PMF is submitted and a relevant officer has advised that the foreign source will not contaminate the Australian product with blood borne pathogens (Part 2(5)(a)-(b)). That means co-processing foreign plasma in an Australian plant used for domestic plasma is not an automatic right and requires affirmative regulator advice based on the PMF. The Determination places the onus on the licence holder to submit the PMF and to obtain regulator approval.

7. Record-keeping is a hard requirement. One of the three limbs of the test for acceptable departures requires that the departure or alternative “will not depart from any applicable record keeping requirements contained in” the PIC/S Guide or Australian Code (Schedule 1, Part 1(2)(a)(iii) and Part 1(2)(b)(iii); Part 2(6)(a)(iii)-(b)(iii)). This elevates record-keeping to a central compliance touchstone and makes record-keeping deficiencies a likely stumbling block for regulator acceptance of deviations.

8. No penalties or appeal procedures are set out in the Determination. The instrument itself does not specify sanctions for failure to comply nor does it set out appeal or review procedures for decisions by relevant officers. Practitioners must therefore connect the Determination to the broader Act and to administrative law pathways to understand consequences and review options. That procedural gap can create uncertainty for licence applicants and manufacturers about remedial steps when a relevant officer refuses to accept an alternative or denies permission to process foreign plasma.

9. Ambiguity in product classification may change applicable regime. The line between a biological that “comprises or contains live animal cells, tissues or organs” and one that does not matters because it determines whether Part 1 (PIC/S Guide) or Part 2 (Australian Code) applies (s 7 and its Note). Manufacturers producing borderline products must be cautious: a misclassification could expose them to the wrong set of obligations and create compliance risk.

10. Multiple external documents to monitor for changes. Although the Determination fixes certain versions at commencement, future amendments (the amending determination noted in s 8) and other updates to the external codes or to TGOs could alter regulatory expectations. Practitioners should note the instrument’s versioning and monitor for amending determinations and for changes in the TGA’s approach to satisfactory demonstrations.

Each of these “gotchas” arises from explicit text in the Determination. Practitioners should structure compliance projects to address the TGA’s satisfaction tests, documentation needs, and to manage timing and versioning issues to avoid inadvertent non-compliance.

Complying with this Determination requires a structured approach that addresses three dimensions: aligning operational procedures with the incorporated GMP documents, assembling and maintaining the required master files and records, and engaging the Therapeutic Goods Administration proactively when departures or cross-border processing are proposed. Below are concrete steps and documentation priorities based on the instrument’s text.

1. Identify the applicable Part and incorporated document for each product or process

• Determine product classification carefully. For each product, decide whether it falls under Schedule 1, Part 1 (PIC/S Guide) or Part 2 (Australian Code). Use s 7 and its Note: biologicals that comprise or contain live animal cells, tissues or organs fall under Part 1; biologicals that do not contain live animal cells/tissues/organs, blood, blood components and haematopoietic progenitor cells fall under Part 2. Confirm if a product is an active pharmaceutical ingredient or a sunscreen, as these are explicitly included under Part 1 (s 6).
• Confirm which external documents and which versions are applicable. Check the definitions in s 4: PIC/S Guide is the Guide as in force 1 September 2025 with specified Annex exclusions; Australian Code is Version 1.0, April 2013, as in force at commencement; TMF and PMF Guideline versions are specified. Also track any amending determination named in s 8 to confirm applicable dates for changes.

2. Map operational procedures to the incorporated Guide or Code

• Conduct a gap analysis against the PIC/S Guide (Schedule 1, Part 1(1)) or the Australian Code (Part 2(1)). For each procedure that the Guide or Code expresses as “should”, annotate whether your current practice follows the recommendation. Under Schedule 1, Part 1(2) and Part 2(6), “should” provisions are binding unless you can demonstrate to a relevant officer that not following them satisfies the three-part test.
• Ensure record-keeping systems capture all data and logs required by the PIC/S Guide or Australian Code. Record-keeping is a discrete limb of the test for departures; departures that would break record-keeping requirements are unlikely to be approved (Schedule 1, Part 1(2)(a)(iii) and Part 2(6)(a)(iii)).

3. Prepare evidence packages for any intended departures or alternatives

• If you intend to deviate from a “should” procedure in the PIC/S Guide or the Australian Code, prepare a demonstration addressing the three prescribed criteria: (i) the failure to adopt the procedure will not increase the risk of harm or injury; (ii) it will not increase the risk of non-compliance with any applicable standard or relevant condition of registration, listing or inclusion; and (iii) it will not depart from applicable record-keeping requirements (Schedule 1, Part 1(2)(a)(i)-(iii) and Part 1(2)(b)(i)-(iii); mirror in Part 2(6)). Use quantitative risk assessments, validation studies, and documented SOPs to support your demonstration.
• Be prepared for discretionary evaluation. The Determination requires that the manufacturer demonstrates these points “to the satisfaction of a relevant officer” (Schedule 1, Part 1(2); Part 2(6)). Document your methodology, assumptions, data sources, and contingency plans to enable the relevant officer to assess the submission.

4. Assemble and maintain required master files for blood-related manufacturing

• Include a technical master file (TMF) with licence applications for steps in the manufacture of blood, blood components or haematopoietic progenitor cells (Schedule 1, Part 2(3)). Ensure the TMF is consistent with the TMF Guideline (s 4 definition) and that it contains the scientific and technical data and the description of the steps of manufacture that the TMF Guideline prescribes.
• Ensure that manufacturing operations conform to the TMF in perpetuity for those products (Schedule 1, Part 2(4)). Update the TMF promptly when manufacturing methods change and maintain version control to show conformance at all stages.

5. For plants processing plasma, follow PMF procedures for foreign sources

• If a blood processing plant processes plasma collected in Australia for Australian products and you propose to process plasma from a source outside Australia in that plant, submit a plasma master file prepared in accordance with the PMF Guideline for that foreign source (Schedule 1, Part 2(5)(a)).
• Obtain affirmative written advice from a relevant officer that, taking into account the plant processes and the submitted PMF, the foreign plasma will not contaminate the Australian product with blood borne pathogens (Part 2(5)(b)). Do not commence processing of foreign plasma for Australian products until this advice is received.

6. Manage interactions with the TGA and plan for timing risk

• Engage with the TGA early when contemplating departures, alternative procedures or processing foreign plasma. Because the Determination vests discretion in the relevant officer and does not specify timelines, early engagement reduces the risk of production delays.
• Keep records of all communications and submissions to the TGA. The Determination’s stress on record-keeping makes contemporaneous documentation of submissions and TGA responses critical.

7. Contracting and supply-chain adjustments

• Update contracts with suppliers, CMOs, and service providers to reflect TMF/PMF obligations and the need to produce documentation that allows demonstration to a relevant officer. Allocate responsibilities and costs for producing TMF/PMF sections and for maintaining records.
• Ensure supply‑chain traceability. Under the three-part test, the TGA will want assurance that raw materials and processes do not increase contamination or compliance risk. Supplier qualifications, certificates of analysis, and audit documentation should be readily available.

8. Monitor versions, amending determinations and excluded Annexes

• Maintain a legal and regulatory tracking process. The Determination binds specific versions and excludes specific Annexes. Track the effective dates stated in s 8 for any amending determination and the differential effective dates for sterile therapeutic goods if applicable (s 8(2)-(3)). Implement compliance changes according to those dates.

9. Audits and internal compliance governance

• Implement internal audits against the PIC/S Guide or Australian Code to ensure continuous compliance. Because departures must demonstrate no increased risk, internal validation, testing and periodic product release testing should be documented and available for regulator review.
• Strengthen quality governance and designate compliance leads to liaise with the relevant officer, prepare TMFs/PMFs and oversee record-keeping systems.

10. Legal and technical support

• Use legal counsel and GMP technical consultants to prepare TMFs, PMFs and alternative demonstrations. Given the regulatory discretion in the Determination, technical expertise matched with legal strategy will mobilise the evidentiary material most likely to satisfy a relevant officer.
• Map potential enforcement linkages back to the Act. Because the Determination does not itself specify sanctions, work with counsel to identify the Act-based consequences for non-compliance and prepare remedial plans.

Concluding compliance note: The Determination makes compliance a documentary and evidentiary exercise as much as an operational one. Success depends on aligning procedures to incorporated Guides/Codes, maintaining robust records, securing robust TMFs/PMFs where applicable, and preparing persuasive, evidence-based submissions for any departures or cross-border plasma processing. The regulator’s satisfaction is the operative test, so prepare to demonstrate non-inferiority in safety, standards compliance and record-keeping.